Final report of University Hospital Hradec Kralove to the clinical trial protocol no. Final report of University Hospital Hradec Kralove to the clinical trial protocol no. Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 0517-31
Abstract
Design of a part of a clinical trial called Randomized, double-blind, active-controlled comparative Phase 3 clinical trial with parallel groups conducted for locally-blind conditions to evaluate the efficacy and safety of a single dose of 150 mg intravenous fosaprepitant dimeglumine to prevent nausea and vomiting caused by chemotherapy administration (CINV), which induces nausea and vomiting is a moderate (moderately emetogenic)